The novel anthraquinone compound Kanglexin (KLX) has been investigated for its potential to prevent EndMT in atherosclerosis by targeting the fibroblast growth factor receptor 1 (FGFR1 ...

Tyra Biosciences' TYRA-300, an oral FGFR3 inhibitor, showed promising efficacy but raised concerns with some FGFR1/2-driven adverse events, causing a significant stock drop. TYRA-300 demonstrated ...

Researchers have identified in a new study that oral infigratinib, an FGFR1-3 selective tyrosine kinase inhibitor, improves ...